CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.

Journal Article (Review)

Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleotides (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.

Full Text

Duke Authors

Cited Authors

  • Murad, YM; Clay, TM; Lyerly, HK; Morse, MA

Published Date

  • August 2007

Published In

Volume / Issue

  • 7 / 8

Start / End Page

  • 1257 - 1266

PubMed ID

  • 17696823

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

Digital Object Identifier (DOI)

  • 10.1517/14712598.7.8.1257

Language

  • eng

Conference Location

  • England